

## Critical role for cytosolic group IVA phospholipase A<sub>2</sub> in early adipocyte differentiation and obesity



Lucía Peña<sup>a,b</sup>, Clara Meana<sup>a,b</sup>, Alma M. Astudillo<sup>a,b</sup>, Gema Lordén<sup>a,b</sup>, Martín Valdearcos<sup>a,b</sup>, Hiroyasu Sato<sup>c</sup>, Makoto Murakami<sup>c,d</sup>, Jesús Balsinde<sup>a,b</sup>, María A. Balboa<sup>a,b,\*</sup>

<sup>a</sup> Instituto de Biología y Genética Molecular, Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Valladolid, 47003, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Spain

<sup>b</sup> Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), 28029 Madrid, Spain

<sup>c</sup> Lipid Metabolism Project, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo 156-8506, Japan

<sup>d</sup> AMED-CREST, Japan Agency for Medical Research and Development, Tokyo 100-0004, Japan

### ARTICLE INFO

#### Article history:

Received 7 April 2016

Received in revised form 2 June 2016

Accepted 10 June 2016

Available online 16 June 2016

#### Keywords:

Phospholipase A<sub>2</sub>

Adipogenesis

Adipocyte

Obesity

Arachidonic acid

### ABSTRACT

Adipogenesis is the process of differentiation of immature mesenchymal stem cells into adipocytes. Elucidation of the mechanisms that regulate adipocyte differentiation is key for the development of novel therapies for the control of obesity and related comorbidities. Cytosolic group IVA phospholipase A<sub>2</sub> (cPLA<sub>2</sub>α) is the pivotal enzyme in receptor-mediated arachidonic acid (AA) mobilization and attendant eicosanoid production. Using primary multipotent cells and cell lines predetermined to become adipocytes, we show here that cPLA<sub>2</sub>α displays a proadipogenic function that occurs very early in the adipogenic process. Interestingly, cPLA<sub>2</sub>α levels decrease during adipogenesis, but cPLA<sub>2</sub>α-deficient preadipocytes exhibit a reduced capacity to differentiate into adipocytes, which affects early and terminal adipogenic transcription factors. Additionally, the absence of the phospholipase alters proliferation and cell-cycle progression that takes place during adipogenesis. Preconditioning of preadipocytes with AA increases the adipogenic capacity of these cells. Moreover, animals deficient in cPLA<sub>2</sub>α show resistance to obesity when fed a high fat diet that parallels changes in the expression of adipogenic transcription factors of the adipose tissue. Collectively, these results show that preadipocyte cPLA<sub>2</sub>α activation is a hitherto unrecognized factor for adipogenesis *in vitro* and *in vivo*.

© 2016 Elsevier B.V. All rights reserved.

### 1. Introduction

Obesity is a very significant health concern worldwide. Although obesity cannot be considered a disease by itself, it is strongly associated with the onset of insulin resistance, type II diabetes and cardiovascular disease [1]. All of these reduce life expectancy and quality, produce early death and collapse healthcare systems. Thus, investigating the mechanisms that support the development of obesity is important for the future discovery of treatments that prevent its occurrence and/or that of its associated disorders.

The expansion of adipose tissue in obesity is caused by an increase in adipocyte number (hyperplasia or adipogenesis) and/or adipocyte size (hypertrophy) [2]. Studies in humans suggest that adipose mass in

adulthood is determined by the tight regulation of the number of adipocytes [3]. Adipogenesis is the complex process through which multipotent mesenchymal precursors commit to the adipocyte lineage and eventually mature into new adipocytes [2,4].

Different models of *in vitro* adipocyte differentiation, including 3T3-L1 and cultured embryonic fibroblasts from mice have provided useful information to help unravel the cascade of events that take place during adipogenesis [5]. Under *in vitro* conditions, adipogenesis requires a period of growth arrest by contact inhibition that ends by treatment with adipogenic factors which promote preadipocytes to re-enter the cell cycle and undergo one or two rounds of mitotic clonal expansion (MCE). Later, cells become permanently growth-arrested and undergo terminal adipocyte differentiation [6–8]. The morphological and genetic changes that occur during the process of adipogenic differentiation are regulated by a cascade of transcription factors. After adipogenic induction, cells immediately and transiently express C/EBPβ and C/EBPδ, implicated in the expression of C/EBPα, PPARγ and SREBP-1c. C/EBPα and PPARγ help each other to maintain their elevated expression throughout the life of the adipocyte and activate the expression of most genes that confer and support the adipocyte phenotype, such as FABP4/aP2,


*Abbreviation:* ADM, adipogenic differentiation medium; AA, arachidonic acid; cPLA<sub>2</sub>α, cytosolic group IVA phospholipase A<sub>2</sub>α; MCE, mitotic clonal expansion; ASCs, adipose stem cell; MEFs, mouse embryonic fibroblast; HFD, high fat diet; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide.

\* Correspondence author at: University of Valladolid School of Medicine, C/ Sanz y Forés 3, 47010 Valladolid, Spain.

E-mail address: [mbalboa@ibgm.uva.es](mailto:mbalboa@ibgm.uva.es) (M.A. Balboa).

**Table 1**  
Primers used for q-PCR.

Name	Gene	Forward	Reverse
Cyclophilin B	<i>Ppib</i>	5'-TGGAGAGCCAAGACAGACA-3'	5'-TGCCGGAGTCGACAATGAT-3'
C/EBP $\alpha$	<i>Cebpa</i>	5'-CAAGAACAGCAACGAGTACCG-3'	5'-TCACGCCTTTCATAACACATTCC-3'
PPAR $\gamma$	<i>Pparg</i>	5'-TGCCAGTTTCGATCCGTAGA-3'	5'-AGGAGCTGTCATTAGGGACATC-3'
FABP4/ap2	<i>Fabp4/ap2</i>	5'-AAGGTGAAGAGCATCATAACCT-3'	5'-TCACGCCTTTCATAACACATTCC-3'
Lipin-1 $\alpha$	<i>Lpin1a</i>	5'-GGTCCCAGCCCCAGTCCTT-3'	5'-GCAGCCTGTGGCAATTC-3'
Lipin-1 $\beta$	<i>Lpin1b</i>	5'-CATGCTTCGAAAGTCCTTCA-3'	5'-GGTTATTCTTTGGCGTCAACT-3'
Adipophilin	<i>Plin2</i>	5'-GACCTTGTCTCCCGCTTAT-3'	5'-CAACCGAATTTGTGGCTC-3'
GLUT4	<i>Glut4</i>	5'-TCGTCATTGGCATTCTGGTTG-3'	5'-AGCTCGTTCTACTAAGAGCAGC-3'
SREBP-1c	<i>Srebp1c</i>	5'-GGAGCCATGGATTGCACATT-3'	5'-CTGAGTGTCTTCTGGAAGG-3'
<b>PLA2 Group</b>			
GIB PLA2	<i>Pla2g1b</i>	5'-GTGTGGCAGTTCGCAATATG-3'	5'-CCTGTCTAAGTCGTCCACTGG-3'
GIIA PLA2	<i>Pla2g2a</i>	5'-TGCTCAATACAGGACCAAGG-3'	5'-GTGGCATCCATAGAAGGCATAG-3'
GIIC PLA2	<i>Pla2g2c</i>	5'-GCTCCAACCCATTTGAATG-3'	5'-CACAGACTGTTTGCACACTCA-3'
GIID PLA2	<i>Pla2g2d</i>	5'-TGCTGGCCGGTATAACTGC-3'	5'-CTGTGGCATCTTTGGGGTGC-3'
GIIE PLA2	<i>Pla2g2e</i>	5'-CCAGTGGACGAGACGGATTG-3'	5'-AGCAGCTCTCTTGTCACTC-3'
GIIF PLA2	<i>Pla2g2f</i>	5'-ACTGGACGGAAGAGCCCAA-3'	5'-GGATGGAGTTTCTGTGTGAT-3'
GIII PLA2	<i>Pla2g3</i>	5'-AGAGACCACAGGCCATTAAAG-3'	5'-GCTGTAGAATGACATGGTCT-3'
GIVA PLA2	<i>Pla2g4a</i>	5'-CAGCACATTATAGTGAACACCA-3'	5'-AGTGTCCAGCATATGCCAAA-3'
GIVB PLA2	<i>Pla2g4b</i>	5'-TGCCCTAGCCCACTTTG-3'	5'-GTTCTGGCCCTCGACTCAGG-3'
GIVC PLA2	<i>Pla2g4c</i>	5'-AGGAGCTGAAACATCGGTATGA-3'	5'-CTGCAAGATGGGATAGGGC-3'
GIVD PLA2	<i>Pla2g4d</i>	5'-CTCGAAGGACCCATCAGT-3'	5'-TTCGGAAGCTTCAGTGTCT-3'
GIVE PLA2	<i>Pla2g4e</i>	5'-ATGGTGACAGACTCCTTCGAG-3'	5'-CCTCTCGTAAAGCTGTGG-3'
GIVF PLA2	<i>Pla2g4f</i>	5'-AGCCATACTGCTACGGAAGAC-3'	5'-TTTGGACAATTTCTGTGTGCT-3'
GV PLA2	<i>Pla2g5</i>	5'-CCAGGGGCTTGCTAGAAC-3'	5'-AGCACCATTCAGTCCATCC-3'
GVI PLA2	<i>Pla2g6</i>	5'-GCCTCGTCAACCCCTCAG-3'	5'-CCTTACCCTGGAATGGGTT-3'
GVII PLA2	<i>Pnpla8</i>	5'-GCAAGAAGTCTTTGTGGAAACA-3'	5'-CTACTTTTGAAGTCCCTTGG-3'
GVIII PLA2	<i>Pnpla6</i>	5'-CGGGTGCAGAAACTCCAG-3'	5'-CGCATAATCTCCGGCCATAGA-3'
GIX PLA2	<i>Pnpla3</i>	5'-TCACCTTCGTGTGCACTC-3'	5'-CCTGGAGCCCTCTCTGAT-3'
GX PLA2	<i>Pnpla2</i>	5'-CTGAGAATCACCATTCCACATC-3'	5'-CACAGCATGAAGGGGAGA-3'
GXI PLA2	<i>Pla2g10</i>	5'-GGATTTCAGGCAAGCAACCAG-3'	5'-GGAAGTACACCGCATAGGG-3'
GXII PLA2	<i>Pla2g12a</i>	5'-TGCTTTCTGTAGGCTGTT-3'	5'-CCGAGTCTCGTAGCATCTG-3'
GXIII PLA2	<i>Pla2g12b</i>	5'-GAACCTGGCTCAGAGTACC-3'	5'-GCAGCTCCATGAAGGAATCCA-3'
GXIV PLA2	<i>Pla2g15</i>	5'-GGTAACCAGTTGGAAGCAA-3'	5'-TTGTCAATCCAGCAGTCAATGAT-3'
GXV PLA2	<i>Pla2g16</i>	5'-CAGCCAGCATCAGTCTGCTT-3'	5'-AGGTACAGGACGGTGACAC-3'



**Fig. 1.** cPLA $_2\alpha$  expression is reduced during ASCs differentiation. (A) SVF cells and adipocytes (AD) were isolated from mice adipose tissue and the levels of mRNA of the PLA $_2$  family genes were analyzed by qPCR. (B) qPCR analysis of adipogenesis related genes in samples shown in A. (C) Homogenates from SVF cells, AD and total adipose tissue were analyzed by immunoblot for cPLA $_2\alpha$  expression.  $\beta$ -Actin was used as loading control. Since AD express low levels of  $\beta$ -Actin, asterisk denotes a nonspecific band that shows similar signal for AD and SVF cells. Lower panel shows the relative quantification of cPLA $_2\alpha$  expression against  $\beta$ -Actin. (D) ASCs were isolated and differentiated *in vitro*. Pictures from day 0 and 9 after differentiation are shown. (E) ASCs mRNA levels for cPLA $_2\alpha$  (*Pla2g4a*) were analyzed by qPCR at different time points during adipogenesis. (F) ASCs homogenates were analyzed for cPLA $_2\alpha$  expression by immunoblot. Relative quantification against  $\beta$ -Actin is shown in the lower panel. Error bars represent the SEM of three independent determinations and statistical significance is indicated \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ . Experiments are representative of at least three different ones.

GLUT4 and PLIN2/Adipophilin [9–11]. *In vivo* models of adipogenesis include the study of adipose tissue enlargement that follows high fat diet (HFD) [1].

cPLA<sub>2</sub>α is one of the most studied members of the PLA<sub>2</sub> superfamily of enzymes, whose common feature is to hydrolyze the fatty acid present in the *sn*-2 position of glycerophospholipids [12,13]. cPLA<sub>2</sub>α is widely expressed in mammalian cells, and is the only PLA<sub>2</sub> that shows preference for arachidonic acid (AA)-containing phospholipids as substrates [14]. During cellular stimulation its activity is regulated by phosphorylation and intracellular Ca<sup>2+</sup> concentrations [15]. A recent unexpected finding among the many functions attributed to cPLA<sub>2</sub>α is that it is necessary for the biogenesis of lipid droplets in various types of cells [16–19]. Adipocytes, also known as fat cells, are the cells where lipid droplets have a most prominent role because of their primary fat-storage function. In this regard, although mice lacking cPLA<sub>2</sub>α and fed a HFD have been described to exhibit smaller epididymal fat pads and adipocytes [20], virtually nothing is known about an involvement of cPLA<sub>2</sub>α in adipose tissue function or even in the adipogenic process *per se*.

Using multipotent adipose-derived stem cells (ASCs), mouse embryonic fibroblast (MEFs) and cell lines, we identify cPLA<sub>2</sub>α as an early key factor for adipocyte differentiation *in vitro*. Furthermore, using cPLA<sub>2</sub>α

KO animals we also reveal a role for this enzyme during high fat diet (HFD)-induced obesity.


## 2. Experimental procedures

### 2.1. Reagents

Antibodies against β-actin (A5441) were obtained from Sigma-Aldrich (St. Louis, MO, USA). Antibodies against PPARγ (07-466) and FABP4/aP2 (AB3515) were purchased from Merck Millipore Corp. (Billerica, MA, USA). Antibodies against C/EBPα (2295), C/EBPβ (3087), cPLA<sub>2</sub>α (2832) and P(Ser505)-cPLA<sub>2</sub>α (2831) were obtained from Cell Signaling Technology (Barcelona, Spain). Antibodies against Cdk2 (643901) and Cyclin A (644001) were from BioLegend (San Diego, CA, USA). Antibodies against the nuclear matrix protein p84 (ab487) were from Abcam (Cambridge, UK) and against p115 (612260) were from BD Biosciences (Franklin Lakes, NJ, USA).

### 2.2. Cell culture and differentiation

3T3-L1 preadipocytes (ATCC CL-173) were maintained in Dulbecco's modified Eagle's medium (DMEM) (Thermo Fisher Scientific Inc.,




**Fig. 2.** cPLA<sub>2</sub>α expression decreases during differentiation in 3T3-L1. (A) qPCR analysis of mRNA levels of PLA<sub>2</sub> family genes in 3T3-L1 cells before and 8 days after adipogenic induction. (B) Pictures of cells treated like in A and stained with Oil Red O are shown. (C) Quantitative analysis of mRNA levels of adipogenesis related genes in samples shown in A. (D) Homogenates from 3T3-L1 cells induced to differentiate for the indicated periods of time were analyzed by immunoblot using specific antibodies against cPLA<sub>2</sub>α and β-Actin as a loading control. (E) Cells treated as in D were analyzed by qPCR for quantification of cPLA<sub>2</sub>α mRNA levels. In all experiment shown error bars represent the SEM of three independent determinations and statistical significance is indicated \*  $p < 0.05$ , \*\*  $p < 0.01$ , \*\*\*  $p < 0.001$ . Experiments are representative of at least three different ones.

Waltham, MA, USA) containing 10% neonatal calf serum (Thermo Fisher Scientific Inc.) plus 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 25 mM HEPES in a humidified incubator with 5% CO<sub>2</sub>. Two days after confluence (differentiation day 0) medium was replaced with DMEM containing 5 µg/ml insulin, 0.5 mM IBMX, 0.25 µM dexamethasone and 10% fetal bovine serum (FBS) (Thermo Fisher Scientific Inc.) (adipogenic differentiation medium 1, ADM1). Two days later, medium was replaced with DMEM containing 5 µg/ml insulin and 10% FBS (ADM2). After three days cells were maintained in medium containing 10% FBS (adipocyte culture medium).

NIH/3T3 (ATCC CRL-1658) were maintained DMEM containing 10% FBS plus 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 25 mM HEPES, and primary MEFs from 14.5-day mouse embryos were maintained DMEM F-12 containing 10% FBS plus 100 U/ml penicillin and 100 µg/ml streptomycin.

Cells were differentiated according to the protocol described for 3T3-L1 cells, but ADM2 and adipocyte culture medium were supplemented with 10 µM of pioglitazone. Also, the concentration of insulin used for MEFs was 10 µg/ml.

Adipocytes and their precursor cells (ASCs) from murine Swiss epididymal white adipose tissue were isolated by collagenase digestion,



**Fig. 3.** cPLA<sub>2</sub>α regulates adipogenesis in primary cells. (A) MEFs from cPLA<sub>2</sub>α<sup>+/+</sup> or cPLA<sub>2</sub>α<sup>-/-</sup> mice were induced to differentiate in adipocytes for 8 days and were stained with Oil Red O. Pictures from cells and culture plates are shown. Right panel shows the quantification of Oil Red O staining. (B) MEFs homogenates from cells treated as in A were analyzed by immunoblot for the expression of the indicated proteins related with adipogenesis. β-Actin or p84 were used as loading controls for total and nuclear proteins. (C) Quantification by qPCR of mRNA levels of the indicated genes from MEFs treated as in A. (D) Confluent NIH-3 T3 cells were treated with siRNA control or against cPLA<sub>2</sub>α for two days, induced to differentiate in adipocytes for 8 days and stained with Oil Red O. Pictures of cells and culture plates are shown. Right panel shows the quantification of Oil Red O staining. (E) Homogenates from NIH-3 T3 cells treated as in D were analyzed by immunoblot for the expression of the indicated proteins related with adipogenesis. Error bars represent the SEM of three independent determinations and statistical significance is indicated \* *p* < 0.05, \*\* *p* < 0.01. The experiments shown are representative of at least three different ones.

as previously described [21]. Cells from the stromal-vascular fraction were cultured on tissue culture plates and were maintained in DMEM F-12 containing 10% FBS plus 100 U/ml penicillin and 100 µg/ml streptomycin in a humidified incubator with 5% CO<sub>2</sub>. Cells attaching to the plates constitute ASCs, which were trypsinized and cryopreserved or reseeded. ASCs were differentiated two days after confluence by adding medium containing 10 µg/ml insulin, 0.5 mM IBMX, 1 µM dexamethasone and 200 µM indomethacin. The medium was changed every 3 days and fully differentiated cells were analyzed after 9 days of culture.

### 2.3. Animals

cPLA<sub>2</sub>α<sup>-/-</sup> (*Pla2g4a*<sup>-/-</sup>) mice and wild type littermates were backcrossed onto the C57BL/6 mice (Japan SLC) for >12 generations [22]. Animals were kept at 23 °C free of pathogens in a 12-h light-dark cycle without restrictions for water or food consumption. At 8 weeks of age, females were changed to a HFD with 32% of crude fat (HFD 32; CLEA Japan) for 16 weeks [23]. All procedures were performed in accordance with approvals by the Institutional Animal Care and Use Committees of Tokyo Metropolitan Institute of Medical Science, Showa University, Japan.

### 2.4. MTT assay

Cell viability was assessed by using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium-bromide (MTT) assay (Sigma-Aldrich). This reagent is reduced by living cells to form an insoluble blue formazan product that can be quantified by absorbance at 570 nm. Cells were treated with 0.5 mg/ml MTT and incubated for 4 h in a CO<sub>2</sub> incubator. Then, cell supernatants were aspirated, cells were treated with isopropanol 100% for 10 min and formazan production was quantified using VersaMax Tunable Microplate Reader (Molecular Devices, Sunnyvale, USA).

### 2.5. Flow cytometry analyses


Cells were trypsinized and collected by centrifugation, washed with PBS, and then fixed in 70% (v/v) cold methanol. Fixed cells were washed with PBS and stained with 50 µg/ml propidium iodide (PI) (Sigma-Aldrich) in the presence of 200 µg/ml RNase A (Sigma-Aldrich) in PBS in the dark for 1 h. Labeled cells were analyzed using a flow cytometry system Gallios™ (Beckman Coulter, Barcelona, Spain), and data were analyzed using the Kaluza™ software.

### 2.6. Immunoblot

Cells were lysed with 20 mM Tris-HCl (pH 7.4), containing 150 mM NaCl, 0.5% Triton X-100, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 1 mM NaF, 1 mM PMSF (Sigma-Aldrich) and a protease inhibitor cocktail (Sigma-Aldrich) at 4 °C. Homogenates were then clarified by centrifugation at 16,000 ×g for 10 min and supernatants used for further analysis.

Extraction of cytoplasmic and nuclear proteins was performed by suspending the cells in 10 mM Tris-HCl (pH 7.5) containing 10 mM NaCl, 3 mM MgCl<sub>2</sub>, 100 µM EGTA, 100 µM Na<sub>3</sub>VO<sub>4</sub>, 1 mM PMSF, a protease inhibitor cocktail (Sigma-Aldrich), 0.5 mM dithiothreitol (Sigma-Aldrich) and 0.05% NP-40 (Merck Millipore Corp.). The cytoplasmic fraction was then clarified by centrifugation at 8000 ×g for 2 min. The pellet containing the nuclei was lysed with 20 mM HEPES (pH 7.9), containing 420 mM NaCl, 1.5 mM MgCl<sub>2</sub>, 100 µM EDTA, 100 µM Na<sub>3</sub>VO<sub>4</sub>, 25% glycerol, 1 mM PMSF and a protease inhibitor cocktail. The nuclear fraction was then clarified by centrifugation at 16,000 ×g for 10 min and supernatants used for further analysis.

Protein from the supernatants was quantified by the BCA protein assay kit (Thermo Fisher Scientific Inc.) and 50 µg of protein was separated by standard 10–15% SDS-PAGE, transferred to polyvinylidene difluoride membranes (Merck Millipore Corp.) and analyzed by immunoblot using specific antibodies. Detection of immunoreactive bands was conducted by chemiluminescence (Thermo Fisher Scientific Inc.) using a Bio-Rad VersaDoc 5000 system. Digital images were analyzed



**Fig. 4.** cPLA<sub>2</sub>α is important for adipogenesis of 3T3-L1 cells. (A–F) Confluent 3T3-L1 cells were treated with siRNA control or against cPLA<sub>2</sub>α for two days, induced to differentiate in adipocytes for 8 days and stained with Oil Red O. Pictures of cells are shown in A. (B) Quantification of differentiated adipocytes from cells analyzed in A. (C) Pictures of cell culture plates are shown. (D) Quantification of Oil Red O staining. (E) Homogenates from cells treated as in A were analyzed by immunoblot for the expression of the indicated proteins related with adipogenesis. (F) Cells treated as in A were analyzed by qPCR for quantification of mRNA levels of the indicated genes. For all the experiments presented error bars represent the SEM of three independent determinations and statistical significance is indicated \*\**p* < 0.01. At least three independent experiments were performed.

for quantitative band densitometry at different time exposures within the linear response defined by Quantity One software (Version 4.5.2; Bio-Rad).

### 2.7. Oil red staining

Differentiated adipocytes were washed with PBS and fixed with 10% formaldehyde in PBS for 1 h, rinsed with 60% isopropanol, and stained with an Oil Red O (Sigma-Aldrich) solution (0.21% Oil Red O in 60% isopropanol) for 10 min. After a final wash with H<sub>2</sub>O, digital images of stained plates were taken using a Nikon inverted optical microscope equipped with a Nikon camera. Quantification of cellular lipid accumulation was achieved by extracting Oil Red O from cells with 100% isopropanol for 10 min and measurement of the absorbance at 500 nm using VersaMax Tunable Microplate Reader (Molecular Devices, Sunnyvale, CA, USA).

### 2.8. RNA interference (siRNA)

To decrease cPLA<sub>2</sub>α expression in cells, double strand siRNA oligonucleotides, against mouse cPLA<sub>2</sub>α were used (MWG Biotech, Ebersberg, Germany) (sequence, 5'-AGCACAUCGUGAGUAAUGAUU-3') [24]. For knockdown, cells were transfected at 90% confluency with control, nonspecific siRNA, or cPLA<sub>2</sub>α siRNA at 40 nM in Opti-MEM® medium (Thermo Fisher Scientific Inc.) using Lipofectamine™ RNAiMAX


(Thermo Fisher Scientific Inc.), according to the manufacturer's protocol. The next day, culture medium was replaced with fresh medium and the cells were incubated for additional 24 h. Knockdown of cPLA<sub>2</sub>α was verified by immunoblot using specific antibodies.

### 2.9. RNA isolation and quantification

RNA was extracted using TRIzol® reagent method (Thermo Fisher Scientific Inc.). First strand cDNA was synthesized from 2 μg of total RNA using the RETROscript® Kit Reverse Transcription for RT-PCR (Thermo Fisher Scientific Inc.) and random primers. The cDNA was amplified by real time qPCR using the KAPA SYBR® FAST qPCR Master Mix Optimized for LightCycler® 480 (Roche Applied Science, Indianapolis, IN, USA) and specific primers for each gene. Sequences of the primers used are stated in Table 1. The relative mRNA abundance for a given gene was calculated using the 2<sup>-ΔΔCT</sup> method, using cyclophilin B as the internal standard [25].

### 2.10. Immunocytochemistry

Cells were seeded in coverslips and fixed with 4% paraformaldehyde in PBS containing 2% sucrose for 20 min. Cells were then permeabilized with 0.1% Triton X-100 for 2 min, washed with PBS, and blocked with 5% BSA in PBS for 30 min. p115 immunostaining was performed by incubating fixed cells with an IgG polyclonal Ab at 1:100 dilution for 1 h



**Fig. 5.** cPLA<sub>2</sub>α acts very early during adipogenesis. (A) 3T3-L1 labeled with 0.5 μCi [<sup>3</sup>H]AA cells were induced to differentiate. [<sup>3</sup>H]AA released to the supernatant was quantified at different time points. (B) 3T3-L1 cells treated with siRNA control or against cPLA<sub>2</sub>α were induced to differentiate for 4 h and AA release was analyzed as in A. (C) 3T3-L1 cells were induced to differentiate for the indicated time points and homogenates were analyzed by immunoblot using specific antibodies for cPLA<sub>2</sub>α or its Ser<sup>505</sup> phosphorylated form. Lower panel represents relative quantification of phosphorylated bands. (D) 3T3-L1 cells were treated with ADM1 or with each its components separately, as indicated. Proteins from homogenates were analyzed as in C. (E) 3T3-L1 transfected with the plasmid EGFP-cPLA<sub>2</sub>α (green) were analyzed by confocal microscopy before (preadipocytes) and 8 days after adipogenic differentiation (adipocytes), as indicated. Nuclei were stained with DAPI (blue) and lipid droplets with Oil Red O (Red). (F) 3T3-L1 adipocytes transfected with EGFP-cPLA<sub>2</sub>α (green) were immunostained with antibodies against p115 (red) and analyzed by confocal microscopy. Error bars represent the SEM of three independent determinations and statistical significance is indicated \* *p* < 0.05, \*\* *p* < 0.01. The experiments shown are representative of at least three different ones.

followed by a goat anti-IgG-Alexa 594 at 1:200. DAPI (Sigma-Aldrich) stainings were carried out. Cells were then mounted with an antifade solution. Fluorescence was monitored by confocal microscopy using a confocal Leica (Mannheim, Germany) TCS SP5X microscope equipped with a Supercontinuum laser. The objective was HC PL APO 63 $\times$ , 1.4 numerical aperture, oil immersion. The fluorescence from EGFP was monitored at 485 nm, from Oil Red O and Alexa 594 at 588 nm, and fluorescence from DAPI was monitored at 405 nm using a blue laser diode.

### 2.11. EGFP-cPLA<sub>2</sub> $\alpha$ transfection

The plasmid EGFP-cPLA<sub>2</sub> $\alpha$  encoding the human cPLA<sub>2</sub> $\alpha$  fused to EGFP in its N-terminus was transfected in preadipocytes 3T3-L1 using Lipofectamine™ LTX and PLUS™ (Thermo Fisher Scientific Inc.) reagents following the manufacturer's instructions [26]. Adipocytes 3T3-L1 were transfected with 3  $\mu$ g of plasmid by electroporation using a Gene Pulse Xcell (Bio-Rad laboratories, Hercules, CA, USA).

### 2.12. AA release assay

Evaluation of AA release was performed as previously described [27]. In brief, the cells were labeled with 0.5  $\mu$ Ci/ml of [5,6,8,9,11,12,14,15-<sup>3</sup>H]AA (Sigma-Aldrich) for 20 h. Cells were then washed, treated with the differentiation cocktail and supernatants were removed for radioactivity quantification. Cell monolayers were overlaid with ice-cold PBS containing 0.05% Triton X-100 and scraped. Radioactivity was quantified by liquid scintillation counting in

supernatants and homogenates, and AA release was referred to total radioactivity for each condition.

### 2.13. Lipid analysis


Lipids from mice gonadal adipose tissue were extracted using the method described by Folch et al. [28]. Lipid classes were separated by thin layer chromatography and their composition in fatty acids were analyzed by GC/MS as previously described [18,29].

### 2.14. Histology and adipocyte quantification

Samples of gonadal adipose tissue were fixed in paraformaldehyde, embedded in paraffin, cut, and stained with hematoxylin and eosin [23]. From micrographs pictures, the area of randomly selected adipocytes was measured using the ImageJ image analysis software. After calculating the frequency distribution for the areas, adipocyte number in WAT was calculated as previously described [30].

### 2.15. Statistics

All values are given as means  $\pm$  SEM. Differences between two groups were assessed by using the unpaired Student's *t*-test. A *p* value <0.05 was considered statistically significant.



**Fig. 6.** cPLA<sub>2</sub> $\alpha$  affects mitotic clonal expansion during adipogenesis. (A) 3T3-L1 cells were treated with siRNA control or against cPLA<sub>2</sub> $\alpha$  and induced to differentiate. Quantification of viable cells was performed by the MTT assay and relative absorbance in each point over control cells at *t* = 0 is shown. (B) Cells treated and induced as in A for 24 h were stained with PI and analyzed by flow cytometry. (C) Representation of percentage of cells in each phase of the cell cycle obtained from the analysis performed in B. (D) Homogenates from cells treated and induced as in A for the indicated periods of time were analyzed by immunoblot using antibodies against Cyclin A, Cdk2 and  $\beta$ -Actin. Relative quantification of specific bands against  $\beta$ -Actin is shown in lower panels. (E) Homogenates from cells treated and induced as in A for the indicated periods of time were analyzed by immunoblot using antibodies against C/EBP $\beta$  and  $\beta$ -Actin. Relative quantification of specific bands against  $\beta$ -Actin is shown in lower panel. Data are representative of three independent experiments done in triplicate, error bars represent the SEM and statistical significance is indicated \*\* *p* < 0.01.

### 3. Results

#### 3.1. cPLA<sub>2</sub>α decreases its expression levels during adipogenesis

We started this work by looking for possible differences in the expression levels of PLA<sub>2</sub> family members between stromal-vascular fraction (SVF) cells, which include adipocyte precursors and adipocytes isolated from white adipose tissue of mice. We noted significant increases in mRNA levels of some PLA<sub>2</sub>s, namely groups IIE, VIA, VIB, VID, VIE and XVI (Fig. 1A), but a very specific change was the disappearance of the mRNA for group IVA PLA<sub>2</sub> (cPLA<sub>2</sub>α). No other PLA<sub>2</sub> gene decreased under these conditions. The expression levels of the preadipocyte specific factor, *Pref1* and the adipocyte markers *Pparg*, *Fabp4*, and *Lipin1* were also evaluated to confirm the nature of the cells under study (Fig. 1B). We also assayed cPLA<sub>2</sub>α protein levels by immunoblot in SVF cells, adipocytes and total adipose tissue, finding that SVF cells have the highest expression and that adipocytes have very low levels of the enzyme (Fig. 1C). We next investigated if during the differentiation process to adipocytes, ASCs decrease their cPLA<sub>2</sub>α levels. To this end, isolated ASCs were differentiated *in vitro* and by analyzing mRNA and protein levels for cPLA<sub>2</sub>α, we confirmed that cPLA<sub>2</sub>α actually decreases during adipogenesis (Fig. 1D–F). When adipocyte differentiation was examined using the 3T3-L1 preadipocytic cell line, essentially the same results were observed regarding PLA<sub>2</sub> family expression pattern and cPLA<sub>2</sub>α expression levels (Fig. 2).


#### 3.2. Reducing the levels of cPLA<sub>2</sub>α in preadipocytes decreases adipogenesis

We next examined the impact of cPLA<sub>2</sub>α on adipogenesis by using multipotent MEFs from cPLA<sub>2</sub>α<sup>-/-</sup> mice, where the expression of the enzyme is completely suppressed (Fig. 3). Elimination of cPLA<sub>2</sub>α expression completely abolished the capacity of MEFs to become adipocytes (Fig. 3), and a drastic reduction in neutral lipid storage (close to 90% reduction, measured by Oil Red O staining) was detected after 8 days of adipogenic induction. Also, the expression of adipocyte specific markers (*Fabp4*/aP2, GLUT4, *Plin2*/Adipophilin) and transcription factors (PPARγ, C/EBPα, SREBP-1c) was abrogated at both protein and mRNA level (Fig. 3B and C).

Multipotent cells such as the NIH/3T3 cell line and the preadipocytic cell line 3T3-L1, were also used in these studies, using siRNA technology to decrease cPLA<sub>2</sub>α (Figs. 3D–E, and 4). The same behavior as described above was observed in the absence of cPLA<sub>2</sub>α. Collectively, these data demonstrate that adipocyte precursors need cPLA<sub>2</sub>α to completely differentiate into adipocytes.

#### 3.3. cPLA<sub>2</sub>α is activated early after adipogenic induction

We next sought to analyze the time period at which cPLA<sub>2</sub>α acts within the differentiation process. As a direct measure of cPLA<sub>2</sub>α activation, we analyzed AA release from 3T3-L1 cells treated with the differentiation cocktail. The results showed a very sharp release of the fatty acid early on, reaching a plateau 3–4 h after induction (Fig. 5A).




**Fig. 7.** Effect of preadipocyte treatment with AA in early adipogenic events. Confluent 3T3-L1 were treated or not with 100 μM AA for two days. After removal of AA cells were induced to differentiate. (A) Quantification of viable cells was performed by the MTT assay of 3T3-L1 cells treated and differentiated for 1 and 2 days. (B) Flow cytometry analysis of 3T3-L1 cells treated and differentiated for 20 h and stained with PI. (C) Representation of the percentage of cells in each phase of the cell cycle quantified as in B. (D) Immunoblot analysis of homogenates from cells differentiated during different periods of time. Antibodies against Cyclin A, Cdk2 and β-Actin were used. Relative quantification of specific bands against β-Actin is shown in lower panels. (E) Homogenates from 3T3-L1 cells were analyzed by immunoblot using antibodies against C/EBPβ and β-Actin. Lower panel represent the densitometric quantification of protein bands shown. The experiments shown are representative of at least three different ones. Error bars represent the SEM and statistical significance is indicated \*  $p < 0.05$ , \*\*  $p < 0.01$ .

Reduction of cPLA<sub>2</sub>α expression significantly affected the release of AA, confirming the importance of the enzyme in the process (Fig. 5B). The time-course of AA release paralleled the phosphorylation of the enzyme in Ser<sup>505</sup>, which is a hallmark of activation (Fig. 5C). We found that FBS caused the same level of phosphorylation as the complete ADM1 (Fig. 5D). By analyzing the localization of cPLA<sub>2</sub>α during the differentiation of 3T3-L1 cells, we found that the enzyme exhibits a cytosolic diffuse localization in preadipocytes, while it localizes mainly in the Golgi in fully differentiated adipocytes (colocalization with the Golgi specific protein p115) (Fig. 5E and F). Analogous localization of cPLA<sub>2</sub>α in the absence of high intracellular Ca<sup>2+</sup> levels has been associated with inactivation of the enzyme [31]. Taken together, these data suggest that cPLA<sub>2</sub>α acts early during adipocyte differentiation.

### 3.4. cPLA<sub>2</sub>α affects several early processes after adipogenic induction

Next, we investigated which of the early events of adipocyte differentiation process were affected by abrogation of cPLA<sub>2</sub>α expression. Mitotic clonal expansion is a well documented event that occurs very early during the differentiation process and is required for adipocyte differentiation [8]. We found that 3T3-L1 cells treated with siRNA against cPLA<sub>2</sub>α experienced diminished proliferation levels as compared to control cells for the first 2 days after adipogenic induction (Fig. 6A). Cell cycle analyses by flow cytometry demonstrated that, while the majority of control cells were at the G<sub>2</sub>/M phase of the cell cycle after 24 h of adipogenic induction, cells with reduced levels of cPLA<sub>2</sub>α underwent a delay that retained many of them in the first phases of the cell cycle (Fig. 6B and C). In agreement with these findings,



**Fig. 8.** Effect of preadipocyte treatment with AA in late adipogenic events. (A) Confluent 3 T3-L1 were treated or not with 100 μM AA for two days. After removal of AA cells were induced to differentiate in adipocytes for different periods of time (days) and were stained with Oil Red O. Pictures from cells and culture plates are shown. Right panel shows the quantification of Oil Red O staining. (B) Homogenates from 3T3-L1 cells treated and induced as in A were analyzed by immunoblot for the expression of the indicated proteins. At least three independent experiments were performed and a representative experiment is shown. (C) qPCR analysis of mRNA levels of the indicated genes were done in 3 T3-L1 treated and differentiated as in A. (D) Homogenates from 3T3-L1 cells treated and differentiated as in A were analyzed by immunoblot using specific antibodies against cPLA<sub>2</sub>α or β-Actin as a loading control. Relative densitometric quantification against β-Actin is shown in lower panel. (E) Confluent 3 T3-L1 were treated or not with 100 μM AA for two days in the presence of 50 μM Indomethacin or the vehicle. Cells were then differentiated to adipocytes (8 days) and stained with Oil Red O. Pictures from culture plates are shown. Right panel shows the quantification of Oil Red O staining. Three independent experiments were done in triplicate. Error bars represent the SEM and statistical significance is indicated \*  $p < 0.05$ , \*\*  $p < 0.01$ .


we found that key factors for cell cycle progression such as cyclin A or Cdk2 had a delayed expression in cells exhibiting reduced levels of cPLA<sub>2</sub>α (Fig. 6D).

Expression of very early transcription factors like C/EBPβ was also delayed in cPLA<sub>2</sub>α-deficient cells (Fig. 6E). As a consequence of it, the expression of transcription factors that are controlled by C/EBPβ, like C/EBPα and SREBP-1c had a reduced expression that could already be noticed at day 2 after adipogenic induction (Fig. 4F). These data indicate that cPLA<sub>2</sub>α is important for early adipogenic events.

### 3.5. Exogenous AA enhances adipogenesis during the cell-contact inhibition state

All the cell systems used in this work show reduced expression levels of cPLA<sub>2</sub>α at the time of adipogenic induction. Thus we reasoned that at least part of the proadipogenic function of cPLA<sub>2</sub>α could be exerted in the preadipocyte when its expression levels are higher. To obtain experimental support for this suggestion, we treated preadipocytes 3T3-L1 with exogenous AA 2 days prior to induction of

adipogenesis, i.e. when proliferation of cells is inhibited by cell contact (confluence phase). As shown in Fig. 7, AA accelerated the expression of the cell cycle-related proteins cyclin A and Cdk2. As a consequence, the AA-treated cells entered earlier into the G<sub>2</sub>/M phase (Fig. 7B and C) and proliferated more than control cells (Fig. 7A). Moreover, AA increased the accumulation of neutral lipids in mature adipocytes (Oil Red O staining, Fig. 8A) as well as the expression of adipocyte markers (*Fabp4/aP2*, *GLUT4*, *Plin2/Adipophilin*) (Fig. 8B and C), and also the expression of early (C/EBPβ, Fig. 7E) and late (PPARγ, C/EBPα and SREBP-1c, Fig. 8B and C) adipocyte transcription factors. We also observed a feedback loop between AA and cPLA<sub>2</sub>α, because AA-treated preadipocytes increased their content of the enzyme (Fig. 8D), an effect that continued during the first two days of adipogenic induction. By treating the cells with the cyclooxygenase inhibitor indomethacin, we found that only part of the effects of AA on adipogenesis was due to prostaglandin generation (Fig. 8E). Overall, these data demonstrate that treatment of preadipocytes with AA during the cell-contact inhibition phase increases adipogenesis.



**Fig. 9.** cPLA<sub>2</sub>α<sup>-/-</sup> mice are protected against obesity induced by HFD. (A) Homogenates from gonadal adipose tissue from cPLA<sub>2</sub>α<sup>+/+</sup> and cPLA<sub>2</sub>α<sup>-/-</sup> mice were analyzed by immunoblot using specific antibodies against cPLA<sub>2</sub>α and β-Actin as a loading control. (B) A picture is shown of cPLA<sub>2</sub>α<sup>+/+</sup> and cPLA<sub>2</sub>α<sup>-/-</sup> mice after 16 weeks in a HFD. (C) cPLA<sub>2</sub>α<sup>+/+</sup> and cPLA<sub>2</sub>α<sup>-/-</sup> mice were weighted weekly during 16 weeks in a HFD or a normal diet. Mean body weights are represented (n = 4). (D–J) Animals were fed a HFD for 16 weeks. (D) Weights of white (WAT) and brown adipose tissue (BAT) are represented normalized by body weight (n = 4). (E) Lean mass is represented (n = 4). (F) Micrographs of hematoxylin and eosin-stained sections of gonadal adipose tissue. Representative pictures are shown. (G) Frequency distribution of adipocyte cell surface area. 1400 adipocytes from each genotype were analyzed (n = 4). Statistical significant difference between the two groups was p = 0.005. (H) Calculated number of adipocytes in WAT is represented n = 4. (I) Lipids from gonadal adipose tissue from animals were analyzed by mass-spectrometry. Mean quantifications for total triglycerides, cholesterol esters and phospholipids is shown. (n = 4) (J) Analysis by qPCR of the mRNA levels of the indicated genes was performed in samples from gonadal adipose tissue from animals (n = 4). Two independent experiments were done. Error bars represent the SEM and statistical significance is indicated \* p < 0.05, \*\* p < 0.01, \*\*\* p < 0.001.

### 3.6. cPLA<sub>2</sub>α KO mice are protected against HFD induced obesity

We next sought to determine the relevance of cPLA<sub>2</sub>α during HFD induced obesity in mice. To this end we fed cPLA<sub>2</sub>α<sup>+/+</sup> and cPLA<sub>2</sub>α<sup>-/-</sup> mice with a HFD for 16 weeks. We observed that cPLA<sub>2</sub>α<sup>-/-</sup> animals gained less weight than cPLA<sub>2</sub>α<sup>+/+</sup> animals (Fig. 9B–C). Also, white adipose tissue (WAT) but not brown adipose tissue (BAT) weight was affected, suggesting a role for cPLA<sub>2</sub>α in the first tissue but not in the second one (Fig. 9D). Importantly, lean mass was not significantly affected by the absence of cPLA<sub>2</sub>α (Fig. 9E). Analysis of the frequency distribution of adipocyte cell surface area demonstrated a significant reduction in the frequency of bigger cells and an enrichment in smaller cells in the adipose tissue of cPLA<sub>2</sub>α<sup>-/-</sup> mice, suggesting a reduced lipid accumulation, or hypertrophy, in these animals (Fig. 9F and G). Moreover, cPLA<sub>2</sub>α<sup>-/-</sup> animals had a decreased number of adipocytes in their WAT pads (Fig. 9H). The phenotype correlated with a reduced accumulation of triglycerides and cholesteryl esters, and a significant increase in phospholipids in the adipose tissue of cPLA<sub>2</sub>α<sup>-/-</sup> animals (Fig. 9I). Analysis of adipocyte markers and transcription factors showed a significantly lower mRNA level for C/EBPβ, SREBP-1c and Adipophilin, and a significant increase in the mRNA for the preadipocytic marker Pref-1 (Fig. 9J).

Together, the data indicate that cPLA<sub>2</sub>α participates in adipogenesis (hyperplasia), and lipid accumulation (hypertrophy) that occur in the adipose tissue during feeding a HFD.

## 4. Discussion

The present study shows that cPLA<sub>2</sub>α is required for adipogenesis of multipotent cells such as MEFs and the cell line NIH/3T3, and the committed preadipocytic cell line 3T3-L1. These data provide support for a key role for cPLA<sub>2</sub>α in *in vitro* differentiation. Furthermore, animals deficient in cPLA<sub>2</sub>α that are subjected to a HFD show a reduced capacity to increase body weight and fat mass, confirming the important role for the enzyme during the enlargement of the adipose tissue in these circumstances.

cPLA<sub>2</sub>α is a unique enzyme within the PLA<sub>2</sub> superfamily in many respects. For instance, cPLA<sub>2</sub>α is the only PLA<sub>2</sub> that shows marked preference for AA chains within glycerophospholipids; it translocates to intracellular membranes in response to an intracellular Ca<sup>2+</sup> rise, and is phosphorylated by MAPKs during activation [12,15,32,33]. It has recently been found that up-regulation of enzymes related to eicosanoid production such as PLA<sub>2</sub> influence the type and quantity of eicosanoids regulating adipose tissue differentiation [34]. The present study adds an interesting unique feature for the AA-releasing cPLA<sub>2</sub>α, as playing a fundamental role at the beginning of adipocyte differentiation. In most cells, cPLA<sub>2</sub>α expression levels are generally stable, its activity being tightly regulated by events triggered after receptor stimulation [12,13,15,26,35,36]. The finding that during adipogenesis, cPLA<sub>2</sub>α levels fall sharply is striking. Cell treatment with glucocorticoids has previously been related with decreases in cPLA<sub>2</sub>α expression levels by affecting *de novo* mRNA synthesis [37]. During adipocytic differentiation *in vitro*, the glucocorticoid dexamethasone, which is present in the differentiation cocktail, may account for the reduction in enzyme levels. Interestingly, we have also detected an important reduction in the levels of cPLA<sub>2</sub>α mRNA and protein between SVF cells and adipocytes from mouse adipose tissue, reflecting that the natural adipocyte differentiation process also proceeds with a reduction of the enzyme. Whether this effect is related with glucocorticoid levels generated during adipogenesis *in vivo* remains to be elucidated.

Along our experimentation we have also found that pretreatment of preadipocytes with AA increases the level of cPLA<sub>2</sub>α. This feedback loop was unexpected, inasmuch as AA is the downstream product of the enzyme. Thus, it is possible that the differentiating effects that AA exerts on preadipocytes may be due to increased cPLA<sub>2</sub>α expression in these cells. The molecular mechanism governing this process remains to be

elucidated. cPLA<sub>2</sub>α has an AP-1 binding site in its promoter that can mediate upregulation of the enzyme [38].

During adipogenesis cPLA<sub>2</sub>α sustains the early expression of several key factors such as the transcription factor C/EBPβ, and cell cycle-related proteins. C/EBPβ is necessary for the expression of the terminal adipogenic transcription factors C/EBPα and PPARγ, and the development of functions that characterize mature adipocytes, such as lipogenesis and lipid accumulation [9,10]. The expression of C/EBPβ and cell cycle-related proteins such as cyclin A is related with increases in cAMP, activation of PKA and phosphorylation of the transcription factor CREB [39,40]. In this regard, it has been described that AA can substitute for IBMX, the molecule present in the adipogenic cocktail that increases cAMP levels, during the induction of adipocyte differentiation [41]. However, if AA and IBMX are added together to preadipocytes, there is a reduction of adipogenesis that can be restored with PKA inhibitors [41]. These effects suggest that under these conditions the levels of cAMP are very high and produce detrimental effects on adipogenesis. However, in a natural adipogenic process where IBMX is not present and cAMP levels are not high, cPLA<sub>2</sub>α could contribute to the generation of cAMP and the propagation of downstream effects. For example, recent evidence has been provided that in addition of prostacyclin and PGE<sub>2</sub>, other downstream products of cPLA<sub>2</sub>α such as leukotriene E<sub>4</sub> may act to elevate the intracellular levels of cAMP [42]. Consistent with this is our finding that pretreatment of preadipocytes with AA during two days without IBMX promotes adipogenesis.

Our *in vivo* studies show that cPLA<sub>2</sub>α plays a role in regulating the expression of C/EBPβ and SREBP-1c during HFD. SREBP-1c is a target for C/EBPβ during adipogenesis, and thus their expression levels are connected [43]. The function of SREBP-1c in adipogenesis is to regulate the expression of genes of lipid metabolism, and the production of endogenous PPARγ ligands [11,44]. This suggests that, although the expression of PPARγ is not affected by cPLA<sub>2</sub>α in animals on a HFD, its activation level could be determined by the endogenous ligands produced by SREBP-1c, impacting in this way on the differentiation process. Thus, by regulating the levels of C/EBPβ and SREBP-1c, cPLA<sub>2</sub>α determines the levels of both adipogenesis and adipocyte hypertrophy *in vivo*.

Not only ASCs exhibit high levels of cPLA<sub>2</sub>α in the adipose tissue, but macrophages also are very rich sources of this enzyme [45]. These are cells with a very high capacity to release AA when activated by many different stimuli [46–48]. In the adipose tissue, obesity promotes infiltration of macrophages, which may account for up to 60% of all cells in the tissue [49], likely increasing the capacity of the tissue to generate AA from phospholipid stores. There are several effectors produced under these circumstances that may act to increase AA release by the macrophages. For example, palmitic acid produced by aberrant lipolysis in stressed adipocytes could activate TLR4 on the surface of macrophages [46]. Also, enhanced production of TNFα during obesity could impact on macrophages to release AA [49]. Thus the possibility exists that, in obesity, activated macrophages that are part of the stromal-vascular fraction of cells, and are very proximal to ASCs, release substantial amounts of AA that in a paracrine manner would impact in ASCs increasing adipogenesis of these cells. In support of this view, a very strong correlation between adipocyte size and macrophage number in adipose tissue has been reported [50].

Collectively our data show that cPLA<sub>2</sub>α is a positive regulator of adipogenesis. cPLA<sub>2</sub>α regulates early adipogenic processes related with the expression of transcription factors and cell cycle progression during the mitotic clonal expansion associated to adipogenesis. Also, in obesity, cPLA<sub>2</sub>α is involved in adipose tissue expansion and neutral lipid deposition. Future research should evaluate whether pharmacological inhibition of the enzyme affects obesity and related comorbidities.

### Conflict of interest

The authors declare that they have no conflicts of interest with the contents of this article.

## Author contributions

L.P. acquisition of data, analyses and interpretation of data, manuscript preparation, statistical analyses. C.M. acquisition of data, analyses and interpretation of data. A.A. acquisition of data, analyses and interpretation of data. G.L. acquisition of data, analyses and interpretation of data. M.V. acquisition of data, analyses and interpretation of data. H.S. acquisition of data, analyses and interpretation of data. M.M. analyses and interpretation of data, manuscript preparation. J.B. analyses and interpretation of data, manuscript preparation. M.A.B. study conception, study design, analyses and interpretation of data, and manuscript preparation.

## Transparency document

The Transparency document associated with this article can be found, in online version.

## Acknowledgments

We thank Montse Duque and Yolanda Noriega for excellent technical assistance. We are grateful to Dr. José Javier García Ramirez (School of Medicine, University of Castilla La Mancha, Albacete, Spain) for providing 3T3-L1 and NIH/3T3 cells, and Dr. Takao Shimizu (Department of Biochemistry and Molecular Biology, the University of Tokyo, Japan) for providing breeding groups of heterozygous cPLA<sub>2</sub>α-deficient mice. This work was supported by the Spanish Ministry of Science and Innovation (Grants SAF2010-18831, BFU2010-18826 and SAF2013-48201-R), the Regional Government of Castile and Leon (Grants BIO39/VA04/10, CSI168A12-1 and BIO/VA03/14) and by grants-in aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan and AMED-CREST from the Japan Agency for Medical Research and Development (MM and HS). L.P. and G.L. were supported by predoctoral fellowships from the Spanish Ministry of Science and Innovation (*Plan de Formación de Personal Investigador* and *Plan de Formación de Profesorado Universitario* programs, respectively). M.V. was supported by a predoctoral fellowship from the Regional Government of Castile and Leon. CIBERDEM is an initiative of *Instituto de Salud Carlos III*.

## References

- [1] M.F. Gregor, G.S. Hotamisligil, Inflammatory mechanisms in obesity, *Annu. Rev. Immunol.* 29 (2011) 415–445.
- [2] T.C. Otto, M.D. Lane, Adipose development: from stem cell to adipocyte, *Crit. Rev. Biochem. Mol. Biol.* 40 (2005) 229–242.
- [3] K.L. Spalding, E. Arner, P.O. Westermark, S. Bernard, B.A. Buchholz, O. Bergmann, L. Blomqvist, J. Hoffstedt, E. Näslund, T. Britton, H. Concha, M. Hassan, M. Rydén, J. Frisén, P. Arner, Dynamics of fat cell turnover in humans, *Nature* 453 (2008) 783–787.
- [4] B.M. Spiegelman, J.S. Flier, Adipogenesis and obesity: rounding out the big picture, *Cell* 87 (1996) 377–389.
- [5] F.M. Gregoire, C.M. Smas, H.S. Sul, Understanding adipocyte differentiation, *Physiol. Rev.* 78 (1998) 783–809.
- [6] V.M. Richon, R.E. Lyle, R.E. McGehee Jr., Regulation and expression of retinoblastoma proteins p107 and p130 during 3T3-L1 adipocyte differentiation, *J. Biol. Chem.* 272 (1997) 10117–10124.
- [7] M. Reichert, D. Eick, Analysis of cell cycle arrest in adipocyte differentiation, *Oncogene* 18 (1999) 459–466.
- [8] Q.Q. Tang, T.C. Otto, M.D. Lane, Mitotic clonal expansion: a synchronous process required for adipogenesis, *Proc. Natl. Acad. Sci. U. S. A.* 100 (2003) 44–49.
- [9] E.D. Rosen, Molecular mechanisms of adipocyte differentiation, *Ann. Endocrinol.* 63 (2002) 79–82.
- [10] P. Tontonoz, B.M. Spiegelman, Fat and beyond: the diverse biology of PPARγ, *Annu. Rev. Biochem.* 77 (2008) 289–312.
- [11] D. Eberlé, B. Hegarty, P. Bossard, P. Ferré, F. Foufelle, SREBP transcription factors: master regulators of lipid homeostasis, *Biochimie* 86 (2004) 839–848.
- [12] E.A. Dennis, J. Cao, Y.H. Hsu, V. Magriotti, G. Kokotos, Phospholipase A<sub>2</sub> enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention, *Chem. Rev.* 111 (2011) 6130–6185.
- [13] J. Balsinde, M.A. Balboa, P.A. Insel, E.A. Dennis, Regulation and inhibition of phospholipase A<sub>2</sub>, *Annu. Rev. Pharmacol. Toxicol.* 39 (1999) 175–189.

- [14] J.D. Clark, L.L. Lin, R.W. Kriz, C.S. Ramesha, L.A. Sultzman, A.Y. Lin, N. Milona, J.L. Knopf, A novel arachidonic acid-selective cytosolic PLA<sub>2</sub> contains a Ca<sup>2+</sup>-dependent translocation domain with homology to PKC and GAP, *Cell* 65 (1991) 1043–1051.
- [15] M. Ghosh, D.E. Tucker, S.A. Burchett, C.C. Leslie, Properties of the group IV phospholipase A<sub>2</sub> family, *Prog. Lipid Res.* 45 (2006) 487–510.
- [16] A. Gubern, J. Casas, M. Barceló-Torns, D. Barneda, X. de la Rosa, R. Masgrau, F. Picatoste, J. Balsinde, M.A. Balboa, E. Claro, Group IVA phospholipase A<sub>2</sub> is necessary for the biogenesis of lipid droplets, *J. Biol. Chem.* 283 (2008) 27369–27382.
- [17] A. Gubern, M. Barceló-Torns, D. Barneda, J.M. López, R. Masgrau, F. Picatoste, C.E. Chalfant, J. Balsinde, M.A. Balboa, E. Claro, JNK and ceramide kinase govern the biogenesis of lipid droplets through activation of group IVA phospholipase A<sub>2</sub>, *J. Biol. Chem.* 284 (2009) 32359–32369.
- [18] C. Guijas, G. Pérez-Chacón, A.M. Astudillo, J.M. Rubio, L. Gil-de-Gómez, M.A. Balboa, J. Balsinde, Simultaneous activation of p38 and JNK by arachidonic acid stimulates the cytosolic phospholipase A<sub>2</sub>-dependent synthesis of lipid droplets in human monocytes, *J. Lipid Res.* 53 (2012) 2343–2354.
- [19] C. Guijas, J.P. Rodríguez, J.M. Rubio, M.A. Balboa, J. Balsinde, Phospholipase A<sub>2</sub> regulation of lipid droplet formation, *Biochim. Biophys. Acta* 1841 (2014) 1661–1671.
- [20] H. Li, N. Yokoyama, S. Yoshida, K. Tsutsumi, S. Hatakeyama, T. Sato, K. Ishihara, S. Akiba, Alleviation of high-fat diet-induced fatty liver damage in group IVA phospholipase A<sub>2</sub>-knockout mice, *PLoS One* 4 (2009), e8089.
- [21] M. Rodbell, Metabolism of isolated fat cells. I. Effects of hormones on glucose metabolism and lipolysis, *J. Biol. Chem.* 239 (1964) 375–380.
- [22] N. Uozumi, K. Kume, T. Nagase, N. Nakatani, S. Ishii, F. Tashiro, Y. Komagata, K. Maki, K. Ikuta, Y. Ouchi, J. Miyazaki, T. Shimizu, Role of cytosolic phospholipase A<sub>2</sub> in allergic response and parturition, *Nature* 390 (1997) 618–622.
- [23] H. Sato, Y. Taketomi, A. Ushida, Y. Isogai, T. Kojima, T. Hirabayashi, Y. Miki, K. Yamamoto, Y. Nishito, T. Kobayashi, K. Ikeda, R. Taguchi, S. Hara, S. Ida, Y. Miyamoto, M. Watanabe, H. Baba, K. Miyata, Y. Oike, M.H. Gelb, M. Murakami, The adipocyte-inducible secreted phospholipases PLA2G5 and PLA2G2E play distinct roles in obesity, *Cell Metab.* 20 (2014) 119–132.
- [24] J. Pindado, J. Balsinde, M.A. Balboa, TLR3-dependent induction of nitric oxide synthase in macrophages via a cytosolic phospholipase A<sub>2</sub>/cyclooxygenase-2 pathway, *J. Immunol.* 179 (2007) 4821–4828.
- [25] K.J. Livak, T.D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>-ΔΔC<sub>T</sub></sup> (ΔΔC<sub>T</sub>), *Methods* 25 (2001) 402–408.
- [26] J. Casas, M.A. Gijón, A.G. Vigo, M.S. Crespo, J. Balsinde, M.A. Balboa, Phosphatidylinositol 4,5-bisphosphate anchors cytosolic group IVA phospholipase A<sub>2</sub> to perinuclear membranes and decreases its calcium requirement for translocation in live cells, *Mol. Biol. Cell* 17 (2006) 155–162.
- [27] J. Casas, C. Meana, E. Esquinas, M. Valdearcos, J. Pindado, J. Balsinde, M.A. Balboa, Requirement of JNK-mediated phosphorylation for translocation of group IVA phospholipase A<sub>2</sub> to phagosomes in human macrophages, *J. Immunol.* 183 (2009) 2767–2774.
- [28] J. Folch, M. Lees, G.H. Sloane Stanley, A simple method for the isolation and purification of total lipides from animal tissues, *J. Biol. Chem.* 226 (1957) 497–509.
- [29] A.M. Astudillo, G. Pérez-Chacón, D. Balgoma, L. Gil-de-Gómez, V. Ruy Pérez, C. Guijas, M.A. Balboa, J. Balsinde, Influence of cellular arachidonic acid levels on phospholipid remodeling and CoA-independent transacylase activity in human monocytes and U937 cells, *Biochim. Biophys. Acta* 1811 (2011) 97–103.
- [30] J. Jo, O. Gavrilova, S. Pack, W. Jou, S. Mullen, A.E. Sumner, S.W. Cushman, V. Periwai, Hypertrophy and/or hyperplasia: dynamics of adipose tissue growth, *PLoS Comput. Biol.* 5 (2009), e1000324.
- [31] S.P. Herbert, A.F. Odell, S. Ponnambalam, J.H. Walker, The confluence-dependent interaction of cytosolic phospholipase A<sub>2</sub>-α with annexin A1 regulates endothelial cell prostaglandin E<sub>2</sub> generation, *J. Biol. Chem.* 282 (2007) 34468–34478.
- [32] G. Pérez-Chacón, A.M. Astudillo, D. Balgoma, M.A. Balboa, J. Balsinde, Control of free arachidonic acid levels by phospholipases A<sub>2</sub> and lysophospholipid acyltransferases, *Biochim. Biophys. Acta* 1791 (2009) 1103–1113.
- [33] A.M. Astudillo, D. Balgoma, M.A. Balboa, J. Balsinde, Dynamics of arachidonic acid mobilization by inflammatory cells, *Biochim. Biophys. Acta* 1821 (2012) 249–256.
- [34] A. Polus, B. Kiec-Wilk, U. Razny, A. Gielicz, G. Schmitz, A. Dembinska-Kiec, Influence of dietary fatty acids on differentiation of human stromal vascular fraction preadipocytes, *Biochim. Biophys. Acta* 1851 (2015) 1146–11455.
- [35] B.J. Pettus, A. Bielawska, P. Subramanian, D.S. Wijesinghe, M. Maceyka, C.C. Leslie, J.H. Evans, J. Freiberg, P. Roddy, Y.A. Hannun, C.E. Chalfant, Ceramide 1-phosphate is a direct activator of cytosolic phospholipase A<sub>2</sub>, *J. Biol. Chem.* 279 (2004) 11320–11326.
- [36] J. Casas, M. Valdearcos, J. Pindado, J. Balsinde, M.A. Balboa, The cationic cluster of group IVA phospholipase A<sub>2</sub> Lys488/Lys541/Lys543/Lys544 is involved in translocation of the enzyme to phagosomes in human macrophages, *J. Lipid Res.* 51 (2010) 388–399.
- [37] M. Dolan-O'Keefe, H.S. Nick, Inhibition of cytoplasmic phospholipase A<sub>2</sub> expression by glucocorticoids in rat intestinal epithelial cells, *Gastroenterology* 116 (1999) 855–864.
- [38] I.T. Lee, C.C. Lin, S.E. Cheng, L.D. Hsiao, Y.C. Hsiao, C.M. Yang, TNF-α induces cytosolic phospholipase A<sub>2</sub> expression in human lung epithelial cells via JNK1/2- and p38 MAPK-dependent AP-1 activation, *PLoS One* 8 (2013), e72783.
- [39] N. Belmonte, B.W. Phillips, F. Massiera, P. Villageois, B. Wdziekonski, P. Saint-Marc, J. Nichols, J. Aubert, K. Saeki, A. You, S. Narumiga, G. Ailhaud, C. Dani, Activation of extracellular signal-regulated kinases and CREB/ATF-1 mediate the expression of CCAAT/enhancer binding proteins beta and -delta in preadipocytes, *Mol. Endocrinol.* 15 (2001) 2037–2049.
- [40] C. Desdouets, G. Matesic, C.A. Molin, N.S. Foulkes, P. Sassone-Corsi, C. Brechet, J. Sobczak-Thépot, Cell cycle regulation of cyclin A gene expression by the cyclic AMP-responsive transcription factors CREB and CREM, *Mol. Cell. Biol.* 15 (1995) 3301–3309.

- [41] L. Madsen, L.M. Pedersen, B. Liaset, T. Ma, R.K. Petersen, S. van den Berg, J. Pan, K. Müller-Decker, E.D. Dülsner, R. Kleemann, T. Kooistra, S.O. Døskeland, K. Kristiansen, cAMP-dependent signaling regulates the adipogenic effect of n-6 polyunsaturated fatty acids, *J. Biol. Chem.* 283 (2008) 7196–7205.
- [42] J.W. Steinke, J. Negri, S.C. Payne, L. Borish, Biological effects of leukotriene E<sub>4</sub> on eosinophils, *Prostaglandins Leukot. Essent. Fat. Acids* 91 (2014) 105–110.
- [43] V.A. Payne, W.S. Au, C.E. Lowe, S.M. Rahman, J.E. Friedman, S. O'Rahilly, J.J. Rochford, C/EBP transcription factors regulate SREBP1c gene expression during adipogenesis, *Biochem. J.* 425 (2009) 215–223.
- [44] J.B. Kim, H.M. Wright, M. Wright, B.M. Spiegelman, ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand, *Proc. Natl. Acad. Sci. U. S. A.* 95 (1998) 4333–4337.
- [45] C.C. Leslie, Kinetic properties of a high molecular mass arachidonoyl-hydrolyzing phospholipase A<sub>2</sub> that exhibits lysophospholipase activity, *J. Biol. Chem.* 266 (1991) 11366–11371.
- [46] V. Ruipérez, A.M. Astudillo, M.A. Balboa, J. Balsinde, Coordinate regulation of toll-like receptor-mediated arachidonic acid mobilization in macrophages by group IVA and group V phospholipase A<sub>2</sub>s, *J. Immunol.* 182 (2009) 3877–3883.
- [47] A.M. Astudillo, G. Pérez-Chacón, C. Meana, D. Balgoma, A. Pol, M.A. del Pozo, M.A. Balboa, J. Balsinde, Altered arachidonate distribution in macrophages from caveolin-1 null mice leading to reduced eicosanoid synthesis, *J. Biol. Chem.* 286 (2011) 35299–35307.
- [48] L. Gil-de-Gómez, A.M. Astudillo, C. Guijas, V. Magrioti, G. Kokotos, M.A. Balboa, J. Balsinde, Cytosolic group IVA and calcium-independent group VIA phospholipase A<sub>2</sub>s act on distinct phospholipid pools in zymosan-stimulated mouse peritoneal macrophages, *J. Immunol.* 192 (2014) 752–762.
- [49] K. McPhillips, W.J. Janssen, M. Ghosh, A. Byrne, S. Gardai, L. Remigio, D.L. Bratton, J.L. Kang, P. Henson, TNF-alpha inhibits macrophage clearance of apoptotic cells via cytosolic phospholipase A<sub>2</sub> and oxidant-dependent mechanisms, *J. Immunol.* 178 (2007) 8117–8126.
- [50] S.P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R.L. Leibel, A., W. Ferrante Jr., Obesity is associated with macrophage accumulation in adipose tissue, *J. Clin. Invest.* 112 (2003) 1796–1808.